2. Search Result
Search Result
Results for "

Relative

" in MedChemExpress (MCE) Product Catalog:

57

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

4

Peptides

2

Inhibitory Antibodies

6

Natural
Products

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-Y1683
    DL-Menthol

    Racementhol
    DL-Menthol is a relative configuration of (-)-Menthol. DL-Menthol relates to the activation of GABAA receptor .
    DL-Menthol
  • HY-103451
    (R,R)-THC

    		Estrogen Receptor/ERR Metabolic Disease
    (R,R)-THC is an ERα agonist and an ERβ antagonist, with Kis of 9.0 nM and 3.6 nM for ERα and ERβ, respectively. (R,R)-THC has higher relative binding affinity for ERβ than ERα with the values of 25 and 3.6 .
    (R,R)-THC
  • HY-W337569
    (±)-Voriconazole

    (±)-UK-109496

    		 Fungal Others
    (±)-Voriconazole ((±)-UK-109496) is a relative configuration of Voriconazole (HY-76200). Voriconazole is an antifungal agent .
    (±)-Voriconazole
  • HY-D1641
    5,5'-Dimethyl BAPTA tetrapotassium

    		Fluorescent Dye Others
    5,5'-Dimethyl BAPTA tetrapotassium is a water-soluble, extracellular membrane metal chelator with relative selectivity for calcium ions .
    5,5'-Dimethyl BAPTA tetrapotassium
  • HY-137583
    Peltatoside

    		Others Inflammation/Immunology
    Peltatoside is a flavone which can be extracted from Annona crassilfora Mart, with an anti-inflammatory activity and can be used for relative research .
    Peltatoside
  • HY-18957A
    rel-Lifirafenib

    rel-BGB-283

    		 Others Cancer
    rel-Lifirafenib (rel-BGB-283) is the relative configuration of Lifirafenib (HY-18957). Lifirafenib is a potent Raf Kinase and EGFR inhibitor .
    rel-Lifirafenib
  • HY-N7259A
    (-)-Isomenthone

    		Others Others
    (-)-Isomenthone is a natural active compound, can be isolated from Mentha haplocalyx. (-)-Isomenthone is a volatile component and relative content of 2.53% in Peppermint from Qinghai .
    (-)-Isomenthone
  • HY-15606
    Tanaproget
    1 Publications Verification

    NSP-989

    		 Progesterone Receptor Endocrinology
    Tanaproget (NSP-989) is a novel nonsteroidal progesterone receptor agonist which can bind to the PR from various species with a higher relative affinity than reference steroidal progestins.
    Tanaproget
  • HY-W011458
    3,5-Dinitro-L-tyrosine sodium

    		Amino Acid Derivatives Others
    3,5-Dinitro-L-tyrosine sodium is a tyrosine derivative. 3,5-Dinitro-L-tyrosine sodium as artificial substrate, has zero activity relative to tyrosine as a substrate for tyrosine aminotransferase .
    3,5-Dinitro-L-tyrosine sodium
  • HY-N4301
    Monensin B

    		Others Others
    Monensin B is a polyketide produced by Streptomyces cinnamonensis. Fermentations of Streptomyces cinnamonensis produce a mixture of Monensin A and Monensin B in a ratio dependent upon the relative concentrations of ethylmalonyl-CoA and methylmalonyl-CoA .
    Monensin B
  • HY-12853
    Mesotrione

    		Reactive Oxygen Species Others
    Mesotrione is a herbicide belongs to the benzoylcyclohexanedione family. Mesotrione is a potent and competitive and reversible inhibitor of HPPD enzyme. Mesotrione is selective to maize due to rapid metabolism and relative high tolerance by the susceptible crop plant .
    Mesotrione
  • HY-146810
    PRMT4-IN-1

    		Histone Methyltransferase Cancer
    PRMT4-IN-1 is a selective inhibitor of PRMT4 (IC50=3.2 nM). PRMT4-IN-1 inhibits MCF7 relative viability .
    PRMT4-IN-1
  • HY-103548
    GSK9027

    		Glucocorticoid Receptor Endocrinology
    GSK9027, as a non-steroidal glucocorticoid receptor (GR) agonist, behaves as a partial agonist on the 2×glucocorticoid response element (GRE) reporter system, and achieves intrinsic activities relative to dexamethasone .
    GSK9027
  • HY-13607A
    (rel)-BMS-641988

    		Androgen Receptor Cancer
    (rel)-BMS-641988 is a relative configuration of BMS-641988. BMS-641988 is a potent nonsteroidal androgen receptor antagonist. BMS-641988 has the potential for the research of prostate cancer .
    (rel)-BMS-641988
  • HY-108637A
    PhiKan 083 hydrochloride

    		MDM-2/p53 Cancer
    PhiKan 083 hydrochloride is a carbazole derivative, which binds to the surface cavity and stabilizes Y220C (a p53 mutant), with a Kd of 167 μM , and a relative binding affinity (Kd) of 150 μM in Ln229 cells .
    PhiKan 083 hydrochloride
  • HY-16684
    AGN-195183

    IRX-5183; VTP-195183; NRX-195183

    		 RAR/RXR Autophagy Cancer
    AGN-195183 (IRX-5183) is a potent and selective agonist of RARα (Kd=3 nM) with improved binding selectivity relative to AGN 193836. AGN-195183 has no activity on RARβ/γ.
    AGN-195183
  • HY-146341
    FAAH-IN-5

    		FAAH MAGL Neurological Disease
    FAAH-IN-5 (Compound 7) is a relative selective, irreversible fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 10.5 nM. FAAH-IN-5 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .
    FAAH-IN-5
  • HY-119943B
    (R)-PF-06256142

    		Others Neurological Disease
    (R)-PF-06256142 is the R enantiomer of PF-06256142 with low active. PF-06256142 is a potent and selective orthosteric D1 receptor agonist that can reduce receptor desensitization relative to dopamine and other catechol-containing agonists .
    (R)-PF-06256142
  • HY-116750
    6-Hydroxykaempferol

    		Tyrosinase Others
    6-Hydroxykaempferol, a flavonoid, is a competitive tyrosinase inhibitor with an IC50 value of 124 μM. 6-Hydroxykaempferol has a Ki value of 148 μM relative to L-DOPA as a substrate and effectively inhibits the activity of the enzyme by binding to the active site of the enzyme .
    6-Hydroxykaempferol
  • HY-P9958A
    Denosumab (anti-TNFSF11)
    1 Publications Verification

    		 RANKL/RANK Cancer
    Denosumab (anti-TNFSF11) is a RANKL inhibitor that is effective against giant cell tumor of bone (GCTB).Denosumab eliminates RANK-positive tumor giant cells and reduces the relative content of proliferative, dense-cell tumor stromal cells .
    Denosumab (anti-TNFSF11)
  • HY-12017
    PF-04217903
    2 Publications Verification

    		 c-Met/HGFR Cancer
    PF-04217903 is a potent ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met. PF-04217903 shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties .
    PF-04217903
  • HY-12017A
    PF-04217903 mesylate
    2 Publications Verification

    		 c-Met/HGFR Cancer
    PF-04217903 mesylate is a potent ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met. PF-04217903 mesylate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties .
    PF-04217903 mesylate
  • HY-16905
    T338C Src-IN-1

    T338C Src-IN-1 is a potent mutant-Src T338C inhibitor; exhibited the most potent inhibition of T338C(IC50=111 nM) relative to WT c-Src (10-fold increase).
    T338C Src-IN-1
  • HY-18947
    SKLB-23bb

    		HDAC Cancer
    SKLB-23bb is a potent and selective inhibitor for HDAC6 with an IC50 of 17 nM and shows 25-fold and 200-fold selectivity relative to HDAC1 (IC50=422 nM) and HDAC8 (IC50=3398 nM), respectively.
    SKLB-23bb
  • HY-160440
    rel-VU6021625

    		Others Others
    rel-VU6021625 is the less active relative configuration of VU6021625 (HY-160440A). VU6021625 is a potent and selective mAChR M4 antagonist with IC50 values of 0.44 nM and 57 nM for human M4, rat M4, respectively .
    rel-VU6021625
  • HY-12017B
    PF-04217903 phenolsulfonate

    		c-Met/HGFR Cancer
    PF-04217903 phenolsulfonate is a potent ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met. PF-04217903 phenolsulfonate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties .
    PF-04217903 phenolsulfonate
  • HY-100689
    Propyl pyrazole triol
    Maximum Cited Publications
    14 Publications Verification

    PPT
    Propyl pyrazole triol (PPT) is a selective estrogen receptor alpha (ERα) agonist. The relative binding affinity of Propyl pyrazole triol for ERα (ERα: 49%) around 410 times higher compared with estrogen receptor beta (ERβ: 0.12%) .
    Propyl pyrazole triol
  • HY-123410
    KM-233

    		Cannabinoid Receptor Cancer
    KM-233 is a classical cannabinoid with good blood brain barrier penetration. KM-233 possesses a selective affinity for the CB2 receptors relative to THC. KM-233 is effective at reducing U87 glioma tumor burden, and can be used for glioma research .
    KM-233
  • HY-115475
    SW-100
    3 Publications Verification

    		 HDAC Neurological Disease
    SW-100, a selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 of 2.3 nM, shows at least 1000-fold selectivity for HDAC6 relative to all other HDAC isozymes. SW-100 displays a significantly improved ability to cross the blood-brain-barrier .
    SW-100
  • HY-18941B
    (rel)-Eglumegad

    (rel)-LY354740; (rel)-Eglumetad

    		 mGluR Neurological Disease
    (rel)-Eglumegad ((rel)-LY354740) is a relative configuration of Eglumegad (HY-18941). Eglumegad is a highly potent and selective group II (mGlu2/3) receptor agonist with EC50s of 5 and 24 nM for transfected human mGlu2 and mGlu3 receptors, respectively .
    (rel)-Eglumegad
  • HY-117953
    RU 59063

    		Prostaglandin Receptor Endocrinology
    RU 59063 is an N-substituted arylthiohydantoin compound with antiandrogenic activity and high relative binding affinity for the rat androgen receptor. RU 59063 is a nonsteroidal androgen receptor that functions as a radioactive AR radioprobe (Ki: 0.71 nM, rAR) when its trifluoromethyl group is replaced by a similar hydrophobic iodine atom .
    RU 59063
  • HY-155165
    Dazonone

    		Phosphodiesterase (PDE) Metabolic Disease
    Dazonone is a phosphodiesterase III inhibitor with the IC50 of 1.68 μM .
    Dazonone
  • HY-120959
    DAUDA

    		Fluorescent Dye Parasite Others
    DAUDA (11-(dansylamino) undecanoic acid) is an environment-sensitive fluorescent fatty acid analogue. DAUDA alters its intensities and fluorescent emission spectra on entry into binding proteins. DAUDA is used to determine the relative affinity of natural fatty acids for polymorphs of the Schistosoma mansoni Sm14 fatty acid-binding protein[1].
    DAUDA
  • HY-112801
    F-1

    		Anaplastic lymphoma kinase (ALK) ROS Kinase Cancer
    F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC50s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALK WT, ROS1 WT, ALK L1196M and ALK G1202R, respectively .
    F-1
  • HY-120006A
    (rel)-AR234960

    		ERK Cardiovascular Disease
    (rel)-AR234960 is an active relative configuration of AR234960. AR234960, a non-peptide MAS (a G protein-coupled receptor) agonist, increases both mRNA and protein levels of CTGF via ERK1/2 signaling in HEK293-MAS cells and adult human cardiac fibroblasts .
    (rel)-AR234960
  • HY-113068
    (rel)-β-Tocopherol

    		Tyrosinase Metabolic Disease
    (rel)-β-Tocopherol is a relative configuration of β-Tocopherol.(±)-β-Tocopherol is a lipid-soluble form of vitamin E with antioxidant activity. β-Tocopherol can inhibit tyrosinase activity and melanin synthesis. β-Tocopherol also can prevent the inhibition of cell growth and of PKC activity caused by d-alpha-tocopherol .
    (rel)-β-Tocopherol
  • HY-148698
    2MD

    		VD/VDR Others
    2MD is an orally active vitamin D analog. 2MD stimulates periosteal bone formation and decreases trabecular bone resorption. Thus 2MD restores trabecular and cortical bone mass and strength. 2MD also regulates intraocular pressure (IOP)-relative genes and reduces IOP in non-human primates .
    2MD
  • HY-12344
    UNC2025
    2 Publications Verification

    		 FLT3 Cancer
    UNC2025 is a potent, ATP-competitive and highly orally active Mer/Flt3 inhibitor with IC50 values of 0.74 nM and 0.8 nM, respectively. UNC2025 is >45-fold selectivity for MERTK relative to Axl (IC50= 122 nM; Ki = 13.3 nM). UNC2025 exhibits an excellent PK properties, and can be used for the investigation of acute leukemia .
    UNC2025
  • HY-12344A
    UNC2025 hydrochloride
    2 Publications Verification

    		 FLT3 Cancer
    UNC2025 hydrochloride is a potent, ATP-competitive, and highly orally active Mer/Flt3 inhibitor with IC50 values of 0.74 nM and 0.8 nM, respectively. UNC2025 hydrochloride is >45-fold selectivity for MERTK relative to Axl (IC50= 122 nM; Ki = 13.3 nM). UNC2025 hydrochloride exhibits an excellent PK properties, and can be used for the investigation of acute leukemia .
    UNC2025 hydrochloride
  • HY-16023B
    (Rac)-Acolbifene

    EM-343; (Rac)-EM-652

    		 Estrogen Receptor/ERR Cancer
    (Rac)-Acolbifene (EM-343; (Rac)-EM-652) is the racemic form of EM652 (estrogen receptor antagonist), has anti-estrogenic and estrogenic activities. (Rac)-Acolbifene (EM-343; (Rac)-EM-652) contains a piperidine ring, shows good pharmacological profile,relative binding affinity (RBA)=380 .
    (Rac)-Acolbifene
  • HY-14552
    Talnetant
    3 Publications Verification

    SB 223412

    		 Neurokinin Receptor Neurological Disease Endocrinology
    Talnetant (SB 223412) is a selective, competitive, brain-permeable NK3 receptor antagonist with a Ki of 1.4 nM in hNK-3-CHO cells. Talnetant is 100-fold more selective for hNK-3 relative to the hNK-2 receptor and has no affinity for hNK-1. Talnetant can be used in schizophrenia-related studies .
    Talnetant
  • HY-14552A
    Talnetant hydrochloride

    SB 223412 hydrochloride; SB 223412-A

    		 Neurokinin Receptor Neurological Disease Endocrinology
    Talnetant (SB 223412) hydrochloride is a selective, competitive, brain-permeable NK3 receptor antagonist with a Ki of 1.4 nM in hNK-3-CHO cells. Talnetant hydrochloride is 100-fold more selective for hNK-3 relative to the hNK-2 receptor and has no affinity for hNK-1. Talnetant hydrochloride can be used in schizophrenia-related studies .
    Talnetant hydrochloride
  • HY-P99735
    Mipeginterferon alfa-2b

    		IFNAR Infection
    Mipeginterferon alfa-2b is an interferon alpha-2b (IFNA2b) analogue, with an average number of 5 substituted among 11 amino groups (one N-terminal and 10 lysine N6). Mipeginterferon alfa-2b has the relative molecular mass of 40 kDa .
    Mipeginterferon alfa-2b
  • HY-128838A
    (rel)-PROTAC ERRα Degrader-1

    		Estrogen Receptor/ERR Others
    (rel)-PROTAC ERRα Degrader-1 is a relative configuration of PROTAC ERRα Degrader-1. PROTAC ERRα Degrader-1 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-1 is an estrogen-related receptor alpha (ERRa) degrader .
    (rel)-PROTAC ERRα Degrader-1
  • HY-N12207
    Neohelmanthicin C

    		Others Others
    Neohelmanthicin C is a phenylpropionic acid compound .
    Neohelmanthicin C
  • HY-107508
    VU-29

    		mGluR Neurological Disease
    VU-29 is a positive allosteric modulator of metabotropic glutamate 5 (mGlu5) receptor (EC50=9 nM and Ki=244 nM for rmGluR5). VU-29 is selective for mGluR5 relative to other mGluR subtypes (EC50: rmGluR1/rmGluR2=557 nM/1.5 μM; hmGluR4=154 nM) .
    VU-29
  • HY-125021
    2BAct
    1 Publications Verification

    		 Eukaryotic Initiation Factor (eIF) Neurological Disease
    2BAct is a highly selective, and orally active eIF2B (eukaryotic initiation factor 2B) activator with an EC50 of 33 nM. 2BAct prevents neurological defects caused by a chronic integrated stress response. 2BAct is able to penetrate the central nervous system (CNS). 2BAct displays improved solubility and pharmacokinetics relative to eIF2B activator ISRIB trans-isomer (HY-12495) .
    2BAct
  • HY-13335
    PKCβ inhibitor 1

    		PKC Apoptosis Cancer
    PKCβ inhibitor 1 is a potent, ATP-competitive, and selective PKCβ inhibitor with IC50s of 21 and 5 nM for human PKCβ1 and PKCβ2, respectively. PKCβ inhibitor 1 exhibits selectivity of more than 60-fold in favor of PKCβ2 relative to other PKC isozymes (PKCα, PKCγ, and PKCε) .
    PKCβ inhibitor 1
  • HY-114324A
    rel-PROTAC PARP1 degrader

    		PROTACs PARP Cancer
    rel-PROTAC PARP1 degrader is the relative configuration of ROTAC PARP1 degrader (HY-114324). ROTAC PARP1 degrader is a PARP1 degrader based on MDM2 E3 ligand. It induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line with an IC50 of 6.12 μM.
    rel-PROTAC PARP1 degrader
  • HY-P1321
    GR231118

    1229U91; GW1229

    		 Neuropeptide Y Receptor Neurological Disease
    GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
    GR231118

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: